



Editor's Note: Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia

Junya Kuroda, Mio Yamamoto, Hisao Nagoshi, Tsutomu Kobayashi, Nana Sasaki, Yuji Shimura, Shigeo Horiike, Shinya Kimura, Akira Yamauchi, Mitsuomi Hirashima, and Masafumi Taniwaki

The editors are publishing this note to alert readers to a concern about this article (1). The β -actin loading control immunoblot in Fig. 3B is a duplication of the caspase-3 immunoblot in Fig. 1F. The authors communicated that they regret this error and noted that they mistakenly used the caspase-3 immunoblot from Fig. 1F as the β -actin loading control immunoblot for Fig. 3B while assembling Fig. 3B. The authors located the β -actin immunoblot they intended to use in Fig. 3B, which is included with an amended Fig. 3B in the Supplementary Data for this notice.

Reference

1. Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, et al. Targeting activating transcription factor 3 by galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. *Mol Cancer Res* 2010;8:994–1001.

Published first August 2, 2024.

Mol Cancer Res 2024;22:779

doi: 10.1158/1541-7786.MCR-24-0507

©2024 American Association for Cancer Research